Cooper Companies (NASDAQ:COO) Director Paul Keel Purchases 4,701 Shares

The Cooper Companies, Inc. (NASDAQ:COO) Director Paul Keel acquired 4,701 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $53.18 per share, with a total value of $249,999.18. Following the acquisition, the director owned 4,701 shares in the company, valued at $249,999.18. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Cooper Companies Trading Down 1.8%

COO opened at $53.27 on Wednesday. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The firm has a market capitalization of $10.13 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 2.21 and a beta of 0.82. The company’s 50 day moving average price is $70.88 and its two-hundred day moving average price is $69.19.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has authorized a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have commented on COO. BNP Paribas Exane cut their target price on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, June 8th. The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a research note on Wednesday, May 27th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday. Bank of America reaffirmed a “neutral” rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Finally, Zacks Research cut Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of “Hold” and a consensus target price of $71.47.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Three Cooper Companies directors reported approximately $1.33 million in combined stock purchases. Paul A. Keel bought 4,701 shares for roughly $250,000, Lawrence Kurzius purchased 10,000 shares for $539,100, and Walter M. Rosebrough Jr. acquired 10,000 shares across two transactions for approximately $541,640. The purchases may indicate that company insiders view the recent selloff as excessive. SEC insider purchase filing
• Positive Sentiment: An analysis titled “A Little More Compelling At This Price” suggests COO’s valuation has become more attractive following the decline, potentially supporting interest from value-oriented investors. Seeking Alpha analysis
• Neutral Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Cooper Companies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds legal and headline risk for shareholders. Rosen Law Firm announcement
• Negative Sentiment: Cooper Companies reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66 and cut revenue guidance to $4.23–$4.25 billion from $4.29–$4.32 billion. The revisions reflect weaker-than-expected contact-lens demand, particularly at CooperVision. Insider Monkey report
• Negative Sentiment: Reports indicated that third-quarter results included U.S. channel inventory destocking and other negative surprises, contributing to the sharp decline in COO shares. Investors are likely focused on how quickly distributors normalize inventories and whether underlying demand improves. HBSS report

Institutional Trading of Cooper Companies

A number of institutional investors have recently bought and sold shares of COO. Avalon Trust Co bought a new position in shares of Cooper Companies in the 2nd quarter worth about $25,000. Root Financial Partners LLC boosted its position in shares of Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 162 shares in the last quarter. SJS Investment Consulting Inc. boosted its position in shares of Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares in the last quarter. Elevation Wealth Partners LLC grew its stake in Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new stake in Cooper Companies during the second quarter worth approximately $30,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.